Eikon reports Q3 2026 results, ESMO oncology data and new prostate cancer INDNov 12Quarterly updateAkari Therapeutics PlcAtrium Therapeutics
Regeneron registry update: new MUC16 trial added; HS, MASH, ALD, melanoma, obesity studies continueNov 12Weekly roundup, 6 itemsALN-CIDEBALN-HSDUpdated
ADARx reports Q3 2026 results, Fast Track for onvuzosiran, three agazisiran trials ongoingNov 12Quarterly updateADARx Pharmaceuticals, Inc.
IDEAYA completes darovasertib NDA, halts Phase 3 OptimUM-010 for enrollment issuesNov 3Quarterly updateAlector, Inc.Allogene Therapeutics
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Alector schedules R&D webinar on wholly owned pipeline after Genentech GCase dealOct 19Clinical readoutAlector, Inc.Atrium TherapeuticsUpdated
Recursion prices $200M offering, reports Sanofi milestone and TUPELO, DAHLIA dataOct 15Quarterly updateAlector, Inc.REC-1245Updated
ADARx prices IPO at $17 per share, AbbVie to buy stakeSep 25FinancingAbbVieADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals files S-1 for Nasdaq IPO under ticker ADRXSep 4FinancingADARx Pharmaceuticals, Inc.inclisiran sodium
Novartis updates Leqvio label; MS study recruiting, thyroid study not yet recruitingAug 21Weekly roundup, 8 itemsGIA632inclisiran
Silexion advances SIL204 into Phase 2/3 trial, reports Q2 2026 resultsAug 14Quarterly updateSilexion Therapeutics Corp
Silence Therapeutics prices $175 million ADS offering at $13.50 per shareAug 12FinancingSilence Therapeutics plc
Silence Therapeutics reports positive Phase 2 topline data for divesiran in polycythemia veraAug 10Clinical readoutSilence Therapeutics plc
Silence Therapeutics reports Q2 2026 results and divesiran trial progressAug 10Quarterly updateSilence Therapeutics plc
Phio reports Q2 2026 results, sets Q3 FDA meeting on PH-762 pathAug 6Quarterly updatePhio Pharmaceuticals Corp.
Sarepta names Michael Severino CEO, reports Q2 2026 results and pipeline updatesAug 5Quarterly updateSarepta Therapeutics, Inc.
Atrium Therapeutics recruiting for Phase 1/2 ATR 1072 trial in PRKAG2 SyndromeJul 31Trial updateATR-1072Atrium Therapeutics